The Challenge of lipid management in patients with diabetes or: Other endocrine disorders

Alberico L. Catapano, Liliana Grigore, Angela Pirillo

Research output: Contribution to journalArticle

Abstract

Diabetes increases the risk of developing cardiovascular disease (CVD), and several guidelines suggest that subjects with diabetes are at high risk of developing CVD. The increased risk can be attributed, at least in part, to associated risk factors, including hypertension and dyslipidaemia. The role of statins in primary and secondary prevention of CVD is well established, and the positive effect has been clearly demonstrated also in patients with type 2 diabetes. A number of studies have evaluated the effect of statin therapy on incident CVD and shown that statin therapy produces a great reduction in cardiovascular risk, but a recent meta-analysis revealed a slight increase in the risk of developing diabetes. Such risk is, however, low, especially when compared with the reduction in cardiovascular events and should not interfere with the choice of treating diabetic patients with a cholesterol-lowering therapy.

Original languageEnglish
Pages (from-to)92-95
Number of pages4
JournalEuropean Endocrinology
Volume7
Issue number2
Publication statusPublished - 2011

Fingerprint

Lipids
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Cardiovascular Diseases
Primary Prevention
Dyslipidemias
Secondary Prevention
Type 2 Diabetes Mellitus
Meta-Analysis
Therapeutics
Cholesterol
Guidelines
Hypertension

Keywords

  • Cardiovascular Risk
  • Combination thera py
  • Diabetes
  • Lipid-lowering
  • Low-density lipoprotein (LDL)
  • Statins

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Endocrine and Autonomic Systems

Cite this

The Challenge of lipid management in patients with diabetes or : Other endocrine disorders. / Catapano, Alberico L.; Grigore, Liliana; Pirillo, Angela.

In: European Endocrinology, Vol. 7, No. 2, 2011, p. 92-95.

Research output: Contribution to journalArticle

@article{f852def0ffb042908d992d0608ffb6aa,
title = "The Challenge of lipid management in patients with diabetes or: Other endocrine disorders",
abstract = "Diabetes increases the risk of developing cardiovascular disease (CVD), and several guidelines suggest that subjects with diabetes are at high risk of developing CVD. The increased risk can be attributed, at least in part, to associated risk factors, including hypertension and dyslipidaemia. The role of statins in primary and secondary prevention of CVD is well established, and the positive effect has been clearly demonstrated also in patients with type 2 diabetes. A number of studies have evaluated the effect of statin therapy on incident CVD and shown that statin therapy produces a great reduction in cardiovascular risk, but a recent meta-analysis revealed a slight increase in the risk of developing diabetes. Such risk is, however, low, especially when compared with the reduction in cardiovascular events and should not interfere with the choice of treating diabetic patients with a cholesterol-lowering therapy.",
keywords = "Cardiovascular Risk, Combination thera py, Diabetes, Lipid-lowering, Low-density lipoprotein (LDL), Statins",
author = "Catapano, {Alberico L.} and Liliana Grigore and Angela Pirillo",
year = "2011",
language = "English",
volume = "7",
pages = "92--95",
journal = "European Endocrinology",
issn = "1758-3772",
publisher = "Touch Briefings",
number = "2",

}

TY - JOUR

T1 - The Challenge of lipid management in patients with diabetes or

T2 - Other endocrine disorders

AU - Catapano, Alberico L.

AU - Grigore, Liliana

AU - Pirillo, Angela

PY - 2011

Y1 - 2011

N2 - Diabetes increases the risk of developing cardiovascular disease (CVD), and several guidelines suggest that subjects with diabetes are at high risk of developing CVD. The increased risk can be attributed, at least in part, to associated risk factors, including hypertension and dyslipidaemia. The role of statins in primary and secondary prevention of CVD is well established, and the positive effect has been clearly demonstrated also in patients with type 2 diabetes. A number of studies have evaluated the effect of statin therapy on incident CVD and shown that statin therapy produces a great reduction in cardiovascular risk, but a recent meta-analysis revealed a slight increase in the risk of developing diabetes. Such risk is, however, low, especially when compared with the reduction in cardiovascular events and should not interfere with the choice of treating diabetic patients with a cholesterol-lowering therapy.

AB - Diabetes increases the risk of developing cardiovascular disease (CVD), and several guidelines suggest that subjects with diabetes are at high risk of developing CVD. The increased risk can be attributed, at least in part, to associated risk factors, including hypertension and dyslipidaemia. The role of statins in primary and secondary prevention of CVD is well established, and the positive effect has been clearly demonstrated also in patients with type 2 diabetes. A number of studies have evaluated the effect of statin therapy on incident CVD and shown that statin therapy produces a great reduction in cardiovascular risk, but a recent meta-analysis revealed a slight increase in the risk of developing diabetes. Such risk is, however, low, especially when compared with the reduction in cardiovascular events and should not interfere with the choice of treating diabetic patients with a cholesterol-lowering therapy.

KW - Cardiovascular Risk

KW - Combination thera py

KW - Diabetes

KW - Lipid-lowering

KW - Low-density lipoprotein (LDL)

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=84860722833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860722833&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84860722833

VL - 7

SP - 92

EP - 95

JO - European Endocrinology

JF - European Endocrinology

SN - 1758-3772

IS - 2

ER -